Claims for Patent: 10,617,693

Summary for Patent: 10,617,693

Title:	Methods of treating and/or preventing actinic keratosis
Abstract:	The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, ##STR00001## to a subject in need thereof.
Inventor(s):	Kwan; Min-Fun Rudolf (Summit, NJ), Lau; Johnson Yiu-Nam (Newport Beach, CA), Kramer; E. Douglas (Stamford, CT), Cutler; David Lawrence (Moorestown, NJ), Fang; Jane (Newport Beach, CA)
Assignee:	Athenex, Inc. (Buffalo, NY)
Application Number:	15/918,100
Patent Claims:	1. A method of treating actinic keratosis comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the following structure: ##STR00007## at a dose from about 0.02 mg/cm.sup.2 to about 0.1 mg/cm.sup.2. 2. The method of claim 1, wherein the compound is administered to an affected area of the subject at a dose from about 0.2 mg to about 5 mg. 3. The method of claim 1, wherein the compound is administered to an affected area of the subject at a dose of about 0.2 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg, about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, about 2.0 mg, about 2.1 mg, about 2.2 mg, about 2.3 mg, about 2.4 mg, about 2.5 mg, about 2.6 mg, about 2.7 mg, about 2.8 mg, about 2.9 mg, about 3 mg, about 4 mg, or about 5 mg. 4. The method of claim 1, wherein the compound is administered to an affected area of the subject at a dose from about 0.025 mg/cm.sup.2 to about 0.1 mg/cm.sup.2. 5. The method of claim 1, wherein the compound is administered to an affected area of the subject at a dose of about 0.02 mg/cm.sup.2, about 0.03 mg/cm.sup.2, about 0.04 mg/cm.sup.2, about 0.05 mg/cm.sup.2, about 0.06 mg/cm.sup.2, about 0.07 mg/cm.sup.2, about 0.08 mg/cm.sup.2, about 0.09 mg/cm.sup.2, or about 0.1 mg/cm.sup.2. 6. The method of claim 2, wherein the affected area is about 1 cm.sup.2 to about 200 cm.sup.2. 7. The method of claim 2, wherein the affected area is about 25 cm.sup.2, about 30 cm.sup.2, about 35 cm.sup.2, about 40 cm.sup.2, about 45 cm.sup.2, about 50 cm.sup.2, about 55 cm.sup.2, about 60 cm.sup.2, about 65 cm.sup.2, about 70 cm.sup.2, about 75 cm.sup.2, about 80 cm.sup.2, about 85 cm.sup.2, about 90 cm.sup.2, about 95 cm.sup.2, or about 100 cm.sup.2. 8. The method of claim 2, wherein the affected area is the skin. 9. The method of claim 1, wherein the compound is administered once a week, once every three days, once every two days, once a day, twice a day, three times a day, or four times a day. 10. The method of claim 1, wherein the compound is administered for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days. 11. The method of claim 1, wherein the compound is administered for 1, 2, 3, 4, or 5 days. 12. The method of claim 1, wherein the compound is administered for 1, 2, 3, 4, 5, or 6 days per week. 13. The method of claim 1, wherein the compound is administered once or twice daily continuously for more than one day per week, followed by discontinuation of the administration for the rest of the week. 14. The method of claim 1, wherein the compound is administered once or twice daily every other day, every three days, every four days, every five days, every six days, or every seven days. 15. The method of claim 1, wherein the compound is administered once or twice daily for two days in a row every three days, every four days, every five days, every six days, or every seven days. 16. The method of claim 1, wherein the compound is administered once or twice daily for three days in a row every four days, every five days, every six days, or every seven days. 17. The method of claim 1, wherein the compound is administered once or twice daily for four days in a row every five days, every six days, or every seven days. 18. The method of claim 1, wherein the compound is administered until the actinic keratosis is fully treated. 19. The method of claim 1, wherein the compound is administered topically. 20. The method of claim 1, wherein the administration of the compound reduces the number and/or severity of, or the number of the subjects that have, local skin reactions or other adverse side effects in the subject compared to other treatments of actinic keratosis. 21. The method of claim 1, wherein the compound is administered once daily. 22. The method of claim 1, wherein the compound is administered for 3 days. 23. The method of claim 1, wherein the compound is administered for 5 days. 24. The method of claim 1, wherein the compound is administered at a dose of about 0.02 mg/cm.sup.2 once daily for 3 days. 25. The method of claim 1, wherein the compound is administered at a dose of about 0.02 mg/cm.sup.2 once daily for 5 days.